ArticleCPT: pharmacometrics & systems pharmacology2026
SCOUT: An Exploratory Approach to Scouting Dose-Relevant Covariates.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying the clinically relevant covariates that drive inter-individual variability is fundamental to precision dosing. However, standard approaches such as stepwise covariate modeling are often limited by the laborious process of evaluating numerous covariate-parameter relationships and primarily focus on statistical significance rather than the clinical relevance of covariate effects on dosing requirements. To address these limitations, we developed the Systematic Covariate Observational Uncovering Technique (SCOUT), an approach that streamlines covariate exploration by shifting the focus from influences on multiple pharmacokinetic (PK) or pharmacodynamic (PD) parameters to those on individual optimal dose, which is a clinically essential metric. This shift simplifies the analysis from a complex many-to-many relationship to a one-to-many evaluation, facilitating rapid identification of factors that substantially influence therapeutic effects. We validated SCOUT across three distinct scenarios: simulation-based verification, real-world amikacin PK data analysis, and complex eribulin PK/PD modeling. Estimated individual optimal doses matched theoretical values with minimal bias. Real-world applications successfully revealed established covariates such as weight and renal function for amikacin and baseline neutrophil count for eribulin. Furthermore, SCOUT provided objective evidence for dosing-interval optimization. By serving as an efficient hypothesis-generating approach, SCOUT enables pharmacometricians to prioritize clinically impactful factors and rationally narrow the search space in formal model building. This approach functions as a "nautical chart" in navigation toward optimal dosing, ultimately supporting more rational and efficient clinical decision-making in drug development and precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.